Drugs that contain Betamethasone Dipropionate; Calcipotriene Hydrate
1. Taclonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US6787529 | LEO PHARMA AS | Topical composition |
Jan, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 25, 2022 |
| Pediatric Exclusivity(PED) | Jan 25, 2023 |
| New Indication(I-659) | Oct 17, 2015 |
Market Authorisation Date: 29 October, 2015
Treatment: Plaque psoriasis
Dosage: SUSPENSION;TOPICAL
More Information on Dosage
TACLONEX family patents
